Viewing Study NCT02625168


Ignite Creation Date: 2025-12-24 @ 5:32 PM
Ignite Modification Date: 2026-03-12 @ 12:01 PM
Study NCT ID: NCT02625168
Status: COMPLETED
Last Update Posted: 2015-12-09
First Post: 2015-12-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
Sponsor: The University of Hong Kong
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Afatinib View
None Erlotinib View
None Metastatic non-small cell lung cancer View
None Efficacy View
None Safety View